A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED) Estimate the efficacy of UK-369,003 MR versus placebo for the treatment of storage male LUTS with and without ED.

• Country None
• organs None
• Specialty None

A PHASE 2a MULTI-CENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERATION OF CP-866,087 IN PRE-MENOPAUSAL WOMEN DIAGNOSED WITH FEMALE SEXUAL AROUSAL DISORDER (FSAD) Assess the effect of 3 doses (1, 3 and 10 mg) of CP-866,087 vs. placebo on female arousal, desire, orgasm and distress in pre-menopausal women on oral contraceptives suffering primarily from Female Se...

• Country None
• organs None
• Specialty None

A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN MODERATE COPD PATIENTS • To characterize the single dose pharmacokinetics of inhaled PF-00610355 in COPD patients. • To evaluate the safety & toleration of single inhaled doses of PF-00610355 in COPD patients.

• Country None
• organs None
• Specialty None

A PHASE IIA RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED 5-WAY CROSS-OVER TRIAL TO EXAMINE THE BRONCHODILATOR EFFECTS OF PF-610,355 AND TO TEST FOR SUPERIORITY VERSUS PLACEBO IN REVERSIBLE ASTHMATIC PATIENTS To test all doses of PF-610,355 for superiority of trough (24 hour post-dose) FEV1 versus placebo. To characterize the relationship of PF-610,355 dose to peak and trough FEV1

• Country None
• organs None
• Specialty None

A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.

• Country None
• organs None
• Specialty None